Jump to content

Elafibranor

From Wikipedia, the free encyclopedia
(Redirected from GFT505)

Elafibranor
Clinical data
Trade namesIqirvo
Other namesGFT505, SureCN815512
License data
Routes of
administration		By mouth
Drug classAntihyperlipidemic
ATC code
Legal status
Legal status
Identifiers
  • 2-[2,6 Dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-1(E)-propenyl]phenoxyl]-2-methylpropanoic acid[2]
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H24O4S
Molar mass384.49 g·mol−1
3D model (JSmol)
  • O=C(O)C(Oc1c(cc(cc1C)\C=C\C(=O)c2ccc(SC)cc2)C)(C)C
  • InChI=1S/C22H24O4S/c1-14-12-16(13-15(2)20(14)26-22(3,4)21(24)25)6-11-19(23)17-7-9-18(27-5)10-8-17/h6-13H,1-5H3,(H,24,25)/b11-6+
  • Key:AFLFKFHDSCQHOL-IZZDOVSWSA-N

Elafibranor (INN[3]), sold under the brand name Iqirvo, is a medication used for the treatement of primary biliary cholangitis.[1][4]

Elafibranor is a dual PPARα/δ agonist.[5][6] Elafibranor and its main active metabolite GFT1007 are peroxisome proliferator-activated receptor (PPAR) agonists, both of which activate PPAR-alpha, PPAR-gamma, and PPAR-delta in vitro.[1]

In June 2024, the US Food and Drug Administration (FDA) granted accelerated approval to elafibranor.[1][7][4]

Medical uses[edit]

Elafibranor is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults who have an inadequate response to ursodeoxycholic acid, or as monotherapy in people unable to tolerate ursodeoxycholic acid.[1][4][8]

Adverse effects[edit]

The most common adverse reactions include weight gain, diarrhea, abdominal pain, nausea, vomiting, arthralgia, constipation, muscle injury, fracture, gastroesophageal reflux disease, dry mouth, weight loss, and rash.[1]

History[edit]

In 2019, the US Food and Drug Administration (FDA) granted elafibranor breakthrough therapy designation, based on phase II data, for the treatment of [[primary biliary cholangitis] in adults with inadequate response to ursodeoxycholic acid (UDCA).[9] The designation was granted to Genfit.[9]

In June 2024, the US FDA granted accelerated approval to elafibranor. The approval was based on positive phase III ELATIVE trial data.[10] The designation was granted to Ipsen.[11]

Research[edit]

It is being studied and developed by Genfit for the treatment of cardiometabolic diseases including type 2 diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease.[12][13][14]

References[edit]

  1. ^ a b c d e f https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218860s000lbl.pdf
  2. ^ Cariou B, Zaïr Y, Staels B, Bruckert E (September 2011). "Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism". Diabetes Care. 34 (9): 2008–14. doi:10.2337/dc11-0093. PMC 3161281. PMID 21816979.
  3. ^ World Health Organization (2015). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 74". WHO Drug Information. 29 (3). hdl:10665/331070.
  4. ^ a b c "Ipsen's Iqirvo receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis". Ipsen (Press release). 10 June 2024. Retrieved 11 June 2024.
  5. ^ US Patent No. 7655641 "96 dpi image of original patent USPTO 7655641" (PDF). Retrieved 31 March 2013.[dead link]
  6. ^ Vázquez-Carrera M (2012). "GFT-505" (PDF). Drugs of the Future. 37 (8): 555–559. doi:10.1358/dof.2012.037.08.1835977. S2CID 258323049.[permanent dead link]
  7. ^ "FDA Roundup: June 11, 2024". U.S. Food and Drug Administration (FDA) (Press release). 11 June 2024. Archived from the original on 11 June 2024. Retrieved 12 June 2024.
  8. ^ "Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis". wallstreet-online.de (in German). 10 June 2024. Retrieved 11 June 2024.
  9. ^ a b "Genfit announces FDA Grant of Breakthrough Therapy Designation to Elafibranor for the Treatment of PBC". Genfit (Press release). 18 April 2019. Archived from the original on 5 June 2024. Retrieved 11 June 2024.
  10. ^ Ipsen (9 May 2024). A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid (Report). clinicaltrials.gov. Archived from the original on 2 May 2024. Retrieved 11 June 2024.
  11. ^ "Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis". wallstreet-online.de (in German). 10 June 2024. Archived from the original on 11 June 2024. Retrieved 11 June 2024.
  12. ^ "Advanced Compound Status" (Press release). Genfit. Archived from the original on 11 April 2013.
  13. ^ "GFT505 Broadens Its Therapeutic Potential" (PDF) (Press release). Archived (PDF) from the original on 10 July 2021. Retrieved 31 March 2013.
  14. ^ Cariou B, Staels B (October 2014). "GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes". Expert Opinion on Investigational Drugs. 23 (10): 1441–8. doi:10.1517/13543784.2014.954034. PMID 25164277. S2CID 3190253.


Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Elafibranor&oldid=1228700890"